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Abstract
Objective: Behcet’s is an idiopathic multi-organ syndrome, which may have onset during childhood. Vascular
involvement is uncommon, with rarely reported coronary aneurysm formation. We present a case report of a
teenager girl who developed recalcitrant life-threatening Behcet’s vasculitis, involving both small and large venous
and arterial systems including a giant coronary aneurysm.
Case report: De-identified data were collected retrospectively in case report format. Although our sixteen year old
female with Behcet’s vasculitis had resolution of many arterial aneurysms, she had persistent venous thrombosis of
large vessels, as well as persistent, giant arterial aneurysms requiring intra-arterial coiling of a lumbar artery and
coronary bypass grafting despite intensive immunosuppression including glucocorticoids, cyclophosphamide,
infliximab, methotrexate, azathioprine and intravenous immunoglobulin.
Conclusions: Vascular manifestations may be seen in Behcet’s syndrome, including asymptomatic coronary
aneurysm, which may be refractory to immunosuppression and ultimately require surgical intervention. Increased
awareness is essential for prompt diagnosis and management.
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Background
Behcet’s syndrome (BS) was initially described as a triad
of symptoms including uveitis with oral and genital
ulcerations [1]. It has since been expanded to include a
constellation of recurring clinical manifestations with
variable mucocutaneous, neurologic, ophthalmologic,
cardiovascular, gastrointestinal, constitutional and mus-
culoskeletal manifestations. Cardiovascular manifesta-
tions are uncommon; vascular lesions may affect both
venous and arterial systems, and can occur in both large
and small arteries. Aneurysms are a rare, potentially life-
threatening manifestation of BS, with coronary aneur-
ysm rarely reported.
We present the case of a teenage girl who developed
medically refractory and life threatening Behcet’s vascu-
litis, involving both small and large venous and arterial
systems including a gigantic coronary aneurysm.
Case report
The patient has given consent for the publication of her
case report. A 16 year old female from the Dominican
Republic presented with a three month history of
malaise, fever, and anorexia and a ten pound weight
loss. She also reported recurrent painful oral and genital
ulcerations, as well as tender erythematous nodules over
her lower legs, suggestive of erythema nodosum. Her
laboratory evaluation was significant for normocytic
anemia and elevated acute phase reactants.
As part of her evaluation for fever, a chest CT and
subsequent magnetic resonance imaging (MRI), includ-
ing MR angiography and venography revealed multiple
arterial aneurysms of bilateral renal and splenic vessels
(the largest splenic aneurysm measured 2.8 × 1.9 cm),
as well as multiple intercostal and lumbar arterial aneur-
ysms (the largest measured 2.9 × 2.5 cm at the level of
the left psoas muscle). There was extensive venous
thrombosis of the right jugular vein, inominate vein and
within the upper segment of the superior vena cava
(SVC), although patency was observed below the level of
the enlarged azygous vein, with multiple prominent
intercostal collaterals within the left hemithorax.
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presumptive diagnosis of BS, including daily oral cyclo-
phosphamide (2 mg/kg/day) and three daily infusions of
intravenous pulse solumedrol (1,000 mg) followed by 60
mg of prednisone daily; the latter was tapered slowly
over the next six months. Therapeutic anticoagulation
was initiated with low molecular weight heparin. Small
patches of cutaneous induration were observed 24-48
hours after subcutaneous injection, suggestive of a
pathergy-like reaction, although without classic papule
or pustule formation.
Follow-up MRI at four months demonstrated com-
plete resolution of splenic, renal, intercostal and most
lumbar aneurysms; however the largest lumbar artery
aneurysm did not regress. Fever and oral ulcerations
resolved and she regained the lost weight. The elevated
acute phase reactants also normalized. After six months
cyclophosphamide was discontinued and maintenance
therapy with monthly infliximab infusions (10 mg/kg/
dose) and weekly oral methotrexate (25 mg) were
initiated. One year after presentation MRI demonstrated
enlargement of the asymptomatic lumbar artery aneur-
ysm, which now measured 5.7 × 5.0 × 5.7 cm. With no
new arterial aneurysms and normal inflammatory mar-
kers, there were no overt signs of active disease. She
underwent successful intravascular coiling of the lumbar
artery aneurysm.
At 18 month follow-up, MRI revealed persistent
venous thrombosis of the right jugular vein and venal
caval system, without new thrombi. Anticoagulation was
discontinued and low dose daily aspirin (81 mg) was
initiated. Although there were no clinical, imaging or
laboratory data suggestive of active vasculitis, the
patient’s immunosuppression was modified to receive
three additional cycles of monthly intravenous cyclopho-
sphamide (increasing doses of 500, 750 and 1,000 mg/
m2) given the possibility that venous clot signified
ongoing inflammation.
At two years, MRI demonstrated an asymptomatic
giant (4.5 × 4.3 × 3.8 cm) predominantly thrombosed
and partially calcified saccular aneurysm of the proximal
left anterior descending (LAD) coronary artery. This was
confirmed by coronary CT angiography (Figure 1). Left
ventricle size and function were normal, with no seg-
mental wall motion abnormalities. Cardiac stress testing
did not reveal any symptomatic or electrocardiographic
findings of myocardial ischemia during exercise.
Despite escalation of therapy with daily oral cyclopho-
sphamide (2.3 mg/kg/day), high dose steroids and war-
farin, five months later an MRA revealed enlargement
(6.7 × 4.2 × 4.9 cm) of the LAD aneurysm. Immunosup-
pression was switched to monthly infliximab infusions
(10 mg/kg), daily azathioprine 100 mg and three
monthly infusions of intravenous immunoglobulin
(IVIG, 2 gm/kg). Four months later, echocardiography
demonstrated further asymptomatic enlargement (8 cm
× 6 cm) of the LAD aneurysm. She continued to have
no clinical or laboratory signs of active BS, and success-
fully underwent two-vessel coronary artery bypass and
was placed on daily prednisone (40 mg) and azathiopr-
ine (150 mg) postoperatively. At five month follow-up
she continues to have no sig n so rs y m p t o m so fa c t i v e
BS or coronary disease on continued azathioprine
therapy.
Discussion
Expanding on the initial description of BS by a derma-
tologist who noted the triad of uveitis with oral and
Figure 1 Cardiac computed tomography images in 2D oblique sagittal view (left) and 3D volume reconstructed view (right)
demonstrating partially thrombosed coronary artery aneurysm involving the proximal segment of the left anterior descending artery.
The aneurysm cavity (double-headed arrows) demonstrates partial thrombosis (low attenuation or darker areas) and widely patent left anterior
descending artery lumen (high attenuation or brighter areas) on the 2D images (left).
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Study Group Classification criteria (Table 1) define BS
as an idiopathic multi-system vasculitis excluding other
disease entities [1,2]. Although originally described in
patients along the “Silk Road”, the syndrome occurs
worldwide with a prevalence of 20-421 per 100,000
adults, though exact numbers are uncertain [3].
The typical age of onset is in the third decade of life;
however up to 20% of patients have onset before age 16
[4]. Our patient represents an atypical example of child-
hood-onset BS, with extensive venous thrombosis and
arterial aneurysms, and progressive vascular disease
despite aggressive immunosuppressive therapy, ulti-
mately requiring endovascular coiling and coronary
bypass surgery. Vascular involvement is reported in up
to 28% of patients [5,6]. Venous manifestations occur in
10-40%, including superficial thrombophlebitis as well as
thrombosis of large veins such as the cerebral venous
sinuses, vena cavae, and jugular venous systems, often
with extensive, reactive collateralization [7]. Arterial
lesions are less common, occurring in up to 7% of
patients, and manifest as aneurysm, thrombosis or ste-
nosis, with the most commonly affected arteries includ-
ing the abdominal aorta, femoral arteries and pulmonary
arteries [5,8-10]. Aneurysm is more frequent than arter-
ial occlusion, although both may occur simultaneously
[8,9,11]. Coronary aneurysm formation is rare, and the
outcome ranges from resolution, persistent morphology,
stenosis, occlusion, dissection or rupture [12]. Although
used, the clinical utility of radiographic evaluation by
MRI or angiography, and laboratory markers is
undetermined.
There are few reports of the histology of Behcet’s vas-
cular lesions which demonstrate non-specific aortitis,
with elements of active inflammation, scar or both [5].
In contrast to the vasculitic inflammatory phase, the
scar stage consists of fibrous thickening of the intima
and adventitia. It is likely that the true incidence of vas-
cular lesions is underestimated, perhaps related to the
fact that patients may have significant vascular lesions
despite being asymptomatic. In fact, a study of 170
autopsies of patients with BS, arterial involvement was
discovered in 57 patients [13].
T h ed e v e l o p m e n to fac o r o n a r ya n e u r y s ma sw e l la s
its increasing size despite treatment is concerning,
although it is possible that this may have been the inevi-
table consequence of the arteritis, with aneurysmal
emergence as the result of degradation of the extracellu-
lar matrix of the coronary artery. Given the rarity and
heterogeneity of the disease and lack of controlled trials
the optimal treatment of patients with BS has not been
standardized. Traditional therapies have included gluco-
corticoids and colchicine; however more recently tumor
necrosis factor blocking agents, such as infliximab, have
also demonstrated clinical utility [14]. Based on an
extensive literature review by the European League
Against Rheumatism (EULAR), the use of cyclophospha-
mide is reserved for severe vascular involvement, based
largely on retrospective studies as no randomized con-
trolled trial has been performed [15].
In childhood, aneurysm of the coronary arteries are
most commonly observed in Kawasaki’s disease, a child-
hood vasculitis with coronary aneurysm formation in up
to 20% of untreated children [16]. The risk of aneurysm
with IVIG treatment is reduced to 5%. Although it is
unknown in KD whether IVIG alters the natural course
of the aneurysm after its formation, in this case IVIG
seemed a reasonable strategy in this recalcitrant patient,
although data pertaining to its use in Behcet’s vasculitis
are absent.
The decision and timing of intravascular or open sur-
gery in Behcet’s aneurysm is controversial. A surgical
procedure may be required in the setting of organ ische-
mia, acute rupture, or increasing size. Surgery may be
complicated by occlusion or recurrence of the aneurysm,
due to a pathergy-like vascular reaction to surgical
trauma [8]. Surmising that the likelihood of a postopera-
t i v ep a t h e r g y - l i k er e s p o n s ei sm o r el i k e l yd u r i n gt h e
Table 1 International Study Group diagnostic (classification) criteria for Behcet’s syndrome (1990)[2]
Recurrent oral ulceration Minor aphthous, major aphthous, or herpetiform ulceration observed by physician or patient
recurring at least three times in one 12 month period
Plus two of the following
Recurrent genital ulceration Aphthous ulceration or scarring, observed by physician or patient
Eye lesions Anterior uveitis, posterior uveitis, cells in the vitreous on slit-lamp examination; or retinal vasculitis
observed by an ophthalmologist
Skin lesions Erythema nodosum observed by the physician or patient, pseudofolliculitis, papulopustular lesions
or acneiform nodules observed by physician in post adolescent patients not on corticosteroid
treatment
Pathergy Development of a papule or pustule 24-48 hours after intradermal injection of the skin with a 20
gauge needle.
Findings applicable only in the absence of
other clinical explanations
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reassuring evidence that there is not ongoing disease.
Though recognizing the unreliable validity of normal
inflammatory markers and imaging studies, even the
asymptomatic patient should be studied before surgery
is pursued. The use of postoperative glucocorticoids has
been demonstrated to minimize the risk of recurrence
of aneurysms, more often given in combination with
other immunosuppressants, such as azathioprine [10].
Although uncommonly seen, coronary aneurysm may
result in significant morbidity and mortality in patients
with BS. The efficacy of aggressive immunosuppression
is unclear, as many patients may be refractory to such
therapy and ultimately require a surgical procedure
unless succumbing to their disease before an appropriate
surgical intervention is offered. Increased awareness
regarding potentially asymptomatic vascular complica-
tions in is critical in the timely care of the patient with
BS.
Consent
Written informed consent was obtained from the patient
for publication of this Case Report and any accompany-
ing images. A copy of the written consent is available
for review by the Editor-in-Chief of this journal.
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